|Bid||9.34 x 900|
|Ask||12.69 x 800|
|Day's range||11.11 - 11.74|
|52-week range||7.21 - 16.37|
|Beta (5Y monthly)||1.62|
|PE ratio (TTM)||N/A|
|Earnings date||10 Nov 2021 - 15 Nov 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||20.00|
One simple way to benefit from the stock market is to buy an index fund. But if you pick the right individual stocks...
Alpine Immune Sciences, Inc. (ALPN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
SEATTLE, September 15, 2021--Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced it has entered into a definitive securities purchase agreement for the sale of common stock and prefunded warrants, as described below, in a private placement with certain institutional and other accredited investors for gross proceeds to Alpine of approximately $91 mill